Načítá se...
Roll out of intraveneous artesunate under named patient programmes in the Netherlands, Belgium and France
BACKGROUND: Intravenous (IV) artesunate is the treatment of choice for severe malaria. In Europe, this treatment is only available in a few countries via named patient programmes (NPPs). As a case study, the legal and organisational aspects and pharmacovigilance of these NPPs and possibilities for h...
Uloženo v:
| Hlavní autoři: | , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2013
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3848968/ https://ncbi.nlm.nih.gov/pubmed/24063858 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-8-150 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|